Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.67 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.67 |
| ▸ | HTR1D | P28221 | 2/20 | 0.67 |
| ▸ | HTR6 | P50406 | 2/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | HTR1E | P28566 | 1/20 | 0.64 |
| ▸ | HTR7 | P34969 | 1/20 | 0.64 |
| ▸ | HTR5A | P47898 | 1/20 | 0.64 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19872632 | 0.89 | GPR17 (0.74) | AKR1C2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL8292621 | 0.88 | MTNR1A (0.70) | AKR1C2ALDH1A1KDM4EHPGDHSD17B10 | |
| Deschlorobenzoyl Indomethacin SCHEMBL454792 | 0.86 | AKR1C2 (1.00) | AKR1C2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL19872790 | 0.83 | KDM4E (0.73) | AKR1C2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL4231080 | 0.83 | HTR1D (0.74) | AKR1C2ALDH1A1KDM4EHSD17B10MTNR1A | |
| SCHEMBL4245648 | 0.82 | AKR1C2 (0.78) | AKR1C2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL8293076 | 0.82 | MTNR1A (0.62) | AKR1C2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL852745 | 0.82 | HSD17B10 (0.67) | AKR1C2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL8555235 | 0.81 | HTR1D (0.76) | AKR1C2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL18509470 | 0.81 | APEX1 (0.59) | AKR1C2ALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019183358-A2 | WHOLE CELL PROCESSES TO PRODUCE NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2018081456-A1 | HIGHLY ACTIVE SELF-SUFFICIENT NITRATION BIOCATALYSTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20180044291-A1 | ARTIFICIAL SELF-SUFFICIENT CYTOCHROME P450S | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-02-15 | — | — | US | disclosed |
| EP-1425010-B8 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | JANSSEN PHARMACEUTICALS INC (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1425010-A4 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | LU TIANBO | 2007-09-20 | — | — | US | disclosed |
| US-7241789-B2 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICAL, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050250771-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | disclosed |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-09-22 | — | — | US | disclosed |
| US-6855722-B2 | Substituted indoles and their use as integrin antagonists | DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| EP-1425010-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002060438-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-5604253-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS | MERCK FROSST CANADA, INC. (CA) | 1997-02-18 | — | — | US | disclosed |
| WO-1996037469-A1 | N-BENZYLINDOL-3-YL PROPANIC ACID DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | ITGA5, ADGRE5, ITGAV | AKR1C2 1077/4885ALDH1A1 1313/4885KDM4E 1575/4885 |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | AKR1C2 1048/4885ALDH1A1 1690/4885KDM4E 1764/4885 |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGAL, ITGA5 | AKR1C2 1039/4885ALDH1A1 1662/4885KDM4E 1966/4885 |
| US-20050250771-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | AKR1C2 1051/4885ALDH1A1 1656/4885KDM4E 1782/4885 |
| US-20180044291-A1 | ARTIFICIAL SELF-SUFFICIENT CYTOCHROME P450S | CYP4F2, POR, CYP4F3 | AKR1C2 224/4885ALDH1A1 449/4885KDM4E 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.